NASDAQ:ARVNArvinas Stock Price, Forecast & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has decreased by 22.3% and is now trading at $34.22. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. The business had revenue of $6.24 million for the quarter, compared to the consensus estimate of $5.18 million. Arvinas had a negative net margin of 171.74% and a negative return on equity of 30.74%. View Arvinas' earnings history.

11 brokers have issued 1 year price objectives for Arvinas' shares. Their forecasts range from $38.00 to $75.00. On average, they anticipate Arvinas' share price to reach $57.10 in the next twelve months. This suggests a possible upside of 66.9% from the stock's current price. View analysts' price targets for Arvinas.

Media stories about ARVN stock have trended negative recently, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arvinas earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Arvinas.

Arvinas saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,300,000 shares, an increase of 13.8% from the June 15th total of 2,900,000 shares. Based on an average trading volume of 608,400 shares, the short-interest ratio is currently 5.4 days. Currently, 12.9% of the company's shares are sold short. View Arvinas' Current Options Chain.

Some companies that are related to Arvinas include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Emergent Biosolutions (EBS), Legend Biotech (LEGN), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Myokardia (MYOK), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), Evotec (EVTCY), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD) and GW Pharmaceuticals PLC- (GWPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), ImmunoGen (IMGN), Krystal Biotech (KRYS), Protalix Biotherapeutics (PLX), Senseonics (SENS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Vaxart (VXRT).

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $34.22.

Arvinas has a market capitalization of $1.34 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]